宜明昂科-B：2023年報

Futu NewsApr 26 21:49 · Announcements

Featured announcements | Xiaopeng and Volkswagen reached a strategic technical cooperation; Sands China's total net revenue increased 42% year over year

Anta Sports: The retail value of Anta brand products achieved a positive year-on-year increase in the number of units in the first quarter; China Building Materials expects a 147% year-on-year increase in net loss for the first quarter.

cls.cnApr 18 08:10

Yiming Angko-B (01541.HK): IMM01 (tidapecip) was approved by the State Drug Administration for phase III clinical trial program

Gelonghui, April 17 | Yiming Angko-B (01541.HK) announced that in April 2024, the Group has obtained approval from the China National Drug Administration for recurrent or refractory (R/R) classic Hodgkin lymphoma (cL) that recurs or progresses after treatment with IMM01 (tidapacept) and tirelizumab in combination therapy with procedural cellular death protein 1 (PD-1) inhibitors. The Group's core product IMM01 (tidapecip) is an innovative targeting differentiation cluster 47 (CD47) molecule. This product is the first to enter China

Gelonghui FinanceApr 17 18:20

Immuneonco Biopharmaceuticals' 2023 Loss Narrows as Other Income Increases

Immuneonco Biopharmaceuticals' (HKG:1541) loss narrowed to 379.5 million yuan or 1.05 yuan per share, in 2023, from 402.9 million yuan, or 1.21 yuan per share, in 2022, according to a Tuesday filing w

MT NewswiresMar 26 19:06

Yiming Enko-B (01541.HK) reduced its annual net loss to 380 million yuan, continuing to rapidly advance the development of drug pipelines

On March 25, GLONGHUI | Yiming Angko-B (01541.HK) announced its annual results. The Group's loss during the year was reduced from RMB 402.9 million for the year ended December 31, 2022 to RMB 379.5 million for the year ended December 31, 2023. R&D expenditure increased 5.3% from RMB 277.3 million for the year ended 31 December 2022 to RMB 291.9 million for the year ended 31 December 2023, mainly due to (i) an increase of RMB 24 in clinical trial expenses due to the progress of clinical drug candidates

Gelonghui FinanceMar 25 22:37

Yiming Onko-B (01541) will continue to support R&D in 2023

Yiming Angko-B (01541) announced its 2023 results, with revenue of about 386,000 yuan and an increase in R&D expenses by 5...

Zhitong FinanceMar 25 22:35